Iluvien meets cost-effectiveness threshold for pseudophakic DME patients, NICE panel finds

The appraisal committee of the National Institute for Health and Care Excellence in the United Kingdom determined a patient access scheme for Iluvien meets the cost-effectiveness threshold for treatment of pseudophakic patients with chronic diabetic macular edema, according to a news release. The patient access scheme for Iluvien (sustained-release fluocinolone acetonide, Alimera Sciences) was proposed after NICE issued guidance in January that it could not recommend the treatment based on cost-effectiveness.

Full Story →